Cardiovascular Health: The SELECT trial showed semaglutide lowered major cardiovascular events by 20% in those with obesity and heart disease, regardless of diabetes
For T1DM patients, insulin replacement is essential due to insufficient endogenous insulin secretion
As GLP 1 receptor activation increases step by step, the brain and digestive tract recalibrate together
This series of phase 3, randomised, double-blind, placebo-controlled clinical trials involved more than 25,000 individuals with overweight or obesity and has extensively demonstrated the efficacy of once-weekly subcutaneous semaglutide 2.4 mg in promoting weight loss [13, 38,39,40,41,42,43,44,45,46]
Sigue leyendo para descubrir cmo funciona Wegovy, sus dosis, efectos secundarios, contraindicaciones y precio